Drugs / F-ARAG
F-ARAG
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07076862 | Dec 2025 → Dec 2028 expected | long COVID-19 | University of California, Davis | Recruiting | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT05096234 | Sep 2021 → May 2022 | non-Hodgkin lymphoma | Stanford University | Terminated | No outcome recorded |
| Phase 1 | NCT04524195 | Feb 2021 → Nov 2023 | non-small cell lung carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT04052412 | Jul 2019 → Dec 2023 | non-small cell lung carcinoma | University of Tennessee | Unknown | No outcome recorded |
| Phase 1 | NCT03367962 | May 2018 → Jun 2023 | graft versus host disease | CellSight Technologies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03142204 | May 2017 → May 2024 | cancer | CellSight Technologies, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02323893 | Feb 2015 → Dec 2017 | cancer | CellSight Technologies, Inc. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06107374 | Nov 2023 → Dec 2025 overdue | non-small cell lung carcinoma | CellSight Technologies, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06084806 | Oct 2023 → Oct 2025 overdue | non-small cell lung carcinoma | CellSight Technologies, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04260256 | Mar 2022 → Mar 2026 | CDK4 linked melanoma | CellSight Technologies, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04726215 | Apr 2021 → Oct 2024 | non-small cell lung carcinoma | CellSight Technologies, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04815096 | Apr 2021 → Oct 2027 expected | COVID-19 | CellSight Technologies, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT03684655 | Sep 2018 → Oct 2025 overdue | HIV infectious disease | CellSight Technologies, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT03311672 | Nov 2017 → Oct 2019 | non-small cell lung carcinoma | University of California, San Francisco | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-ARAG | ChEMBL registry synonym — accepted as the source's own label CHEMBL3143549 ↗ |
| Known as | 18F-AraG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04052412 ↗ |
| Known as | 2'-deoxy-2'-[(18)F]fluoro-9-β-D-arabinofuranosylguanine | “To test the possibility of using a radiofluorinated AraG as an imaging agent, we have synthesized 2'-deoxy-2'-[(18)F]fluoro-9-β-D-arabinofuranosylguanine ([(18)F]F-AraG) and...” PMID 20838911 ↗ Oct 2011 |
| Known as | 2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine | “[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)” NCT03684655 ↗1“[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)” NCT04815096 ↗ |
| Known as | [ 18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D- arabinofuranosylguanine; trade name VisAcT) | “[ 18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D- arabinofuranosylguanine; trade name VisAcT)” NCT05096234 ↗ |
| Known as | [(18)F]F-AraG | “The aim of this study was to assess the value of [18F]F-AraG PET imaging as a noninvasive method for evaluation of system-wide immune status of patients with non-small cell...” PMID 39448270 ↗ Dec 202414“To test the possibility of using a radiofluorinated AraG as an imaging agent, we have synthesized 2'-deoxy-2'-[(18)F]fluoro-9-β-D-arabinofuranosylguanine ([(18)F]F-AraG) and...” PMID 20838911 ↗ Oct 2011 “Detection of Graft Versus Host Disease With [18F]F-AraG, a Positron Emission Tomography Tracer for Activated T Cells” NCT03367962 ↗ |
| Known as | F-ARAG F-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3143549 ↗ |
| Known as | VisAcT | “a PET tracer called \[18F\]F-AraG (VisAcT)” NCT03142204 ↗ |
| Modality | Diagnostic / imaging agent | “a positron emission tomography (PET) imaging tracer” NCT02323893 ↗ |
| Route | Intravenous | “will be intravenously injected” NCT02323893 ↗ |